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cells; PBS, phosphate-buffered saline; IF, intensity of ﬂ
Htc, hematocrit; FP, ferriprotoporphyrin IX.We provide two simple low-cost and low-tech procedures to measure with good precision and accuracy
the binding and internalization into human erythrocytes of chloroquine and other aminoquinolines. The
methods are based on the high ﬂuorescence of the quinoline ring and are complementary. Method A eval-
uates residual drugs in the supernatants of treated erythrocytes, whereas method B quantiﬁes the total
uptake by whole cells and the fraction bound to the membranes. Drug uptake is dose dependent and
related to the number of erythrocytes. These assays could be useful when studying the cell interaction
of quinoline-type compounds not available in the radioactive form.
 2008 Elsevier Inc. All rights reserved.Chloroquine (CQ)1 has been one of the most successful antima-
larial drugs due to its speciﬁcity, safety, and stability, but it is now
largely ineffective in most malaria endemic areas because of the
emergence of Plasmodium falciparum (Pf) resistance. Artemisin-based
combination therapy is currently recommended as ﬁrst-line treat-
ment for uncomplicated malaria, but there is a continuous necessity
of new drugs or new drug combinations to increase efﬁcacy and de-
lay the onset of resistance [1,2].
We recently synthesized new quinolizidinyl and quinolizidinyl–
alkyl derivatives of 4-aminoquinolines in which a terminal bulky
bicyclic basic moiety was introduced to prevent the metabolic oxi-
dation that limits the usefulness of quinoline compounds. Leads
that are highly effective in vitro against several drug-resistant
strains of Pf and in vivo in the murine Plasmodium berghei model
were obtained [3]. Two of these compounds, named AM1 and
AP4b, were selected for further characterization (Fig. 1). Prelimin-
ary pharmacokinetic data indicate that more than 60% of com-
pounds are bound to the corpuscular blood fraction. This is
consistent with what has been described previously for CQ [4].
Since the early 1970s, the capacity of red blood cells (RBC) unin-
fected or infected by different strains of Pf to bind CQ or other ami-
noquinoline antimalarial drugs has been evaluated using 3H- or
14C-labeled compounds. The uptake of the drug by RBC was quan-
tiﬁed by counting the radioactivity that is associated with the cell
pellet or that disappeared from the incubation medium after cen-
trifugation [5–7]. To avoid the laborious synthesis and risky use
of radiolabeled compounds, we developed two simple, low-cost,ll rights reserved.
odeo Salè).
m falciparum; RBC, red blood
uorescence; Hb, hemoglobin;and reproducible methods based on the high ﬂuorescence of the
quinoline ring to evaluate binding/internalization of the quinolines
to human RBC.
Method A measures the residual ﬂuorescence in the superna-
tants of drug-treated RBC, whereas method B was optimized to dif-
ferentiate and quantify the amount of compound bound to RBC
membranes or internalized by RBC. The experiments were done
using fresh RBC from healthy donors. Cells were washed three
times with 5 mM cold phosphate-buffered saline (PBS)–glucose
and incubated with the drugs at 37 C in the optimized conditions
described below.
In preliminary experiments, we determined the ﬂuorescence
spectra of the quinolines under study. For each compound,
the excitation wavelengths (CQ = 258 nm, AM1 = 255 nm, AP4b =
253 nm) corresponding to the maximum emission at 380 nm were
chosen. Speciﬁc excitation wavelengths must be properly selected
for each quinoline derivative.
In addition, because quinolines are weak bases, the intensity of
ﬂuorescence (IF) is strongly dependent on pH, with the highest IF
being in highly basic media (pH > 12.0) in the deprotonated form.
For example, at acidic pH, CQ IF is negligible, whereas at neutral
pH (PBS), IF is approximately 45% compared with that measured
at pH > 12.0 (not shown). Two factors could contribute to the lower
ﬂuorescence at neutral pH: (i) a reduced electronic transition due
to the partially protonated form of the drug and (ii) self-quenching
due to p–p interaction among the quinoline rings. A linear rela-
tionship between CQ concentration and IF was observed between
0 and 2 lM with a detection limit at 0.15 lM. Concentrations of
CQ higher than 2 lM were not linearly related to IF (not shown).
AM1 and AP4b behaved similarly. Variations in temperature do
not interfere with IF.
For method A, preliminary experiments were performed to
standardize the method and minimize the interference of hemo-
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Fig. 1. Molecular structures of the compounds used in this study.
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Fig. 2. (A) Method A: representative experiment showing the decrease of AM1
ﬂuorescence when incubated with human RBC. Shown are ﬂuorescence emission
spectra of 1 lM AM1 (excitation at 255 nm) alone (a: continuous line), in the
presence of RBC supernatant (2% Htc in 2 ml ﬁnal volume) (b: dashed line), or in the
presence of RBC (c: dotted line). The bottom line (d) represents the baseline
ﬂuorescence of free Hb in the supernatants from control RBC. AU, arbitrary units. (B)
Method B: dose-dependent binding of CQ, AM1, and AP4b to human RBC. The inset
shows uptake of CQ as function of the number of RBC. Data represent the means of
ﬁve different experiments run in triplicate. Vertical error bars should be considered
as symmetric.
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ﬁlter effect leading to misinterpretation of the data, the measure-
ments were performed in very diluted samples whose absorbance
at the excitation wavelength was less than 0.07. During the assay,
trace amounts of Hb may be released by RBC depending on hemat-
ocrit (Htc). Hb ﬂuorescence from control RBC was evaluated and
subtracted from all samples. In addition, free Hb may cause
quenching of IF of the drugs. For this reason, the emission spec-
trum of the drug in the presence of the supernatant of RBC was
preferred as a control instead of the spectrum of the drug alone.
The quenching due to the presence of free Hb is measured by the
difference of IF between the two spectra.
The assay was performed by incubating RBC at 1% to 4% Htc in
PBS for different lengths of time (10–180 min) in the presence of
drug concentrations ranging from 1 to 0.25 lM in 24-well plates
at a ﬁnal volume of 2 ml. The incubation was performed at room
temperature or 37 C in an incubator without CO2 to avoid the
acidiﬁcation of the medium and the decrease of IF. Plates were
then centrifuged at 600g for 10 min, and supernatants were recov-
ered for ﬂuorimetric analysis using a PerkinElmer LS50 ﬂuorimeter.
Quartz cuvettes were always used for the ﬂuorescence measure-
ments. The areas of the peaks were calculated by FLWinLab
software.
Binding of the different quinolines to RBC was very rapid (pla-
teau after 10 min) and dependent on the concentration of RBC.
The experimental conditions allowing a rapid and sensitive analy-
sis, free of signiﬁcant quenching and/or interferences, were set as
follows: 2% Htc, 10 min incubation, and 1 lM drugs at 37 C or
room temperature (binding was not signiﬁcantly different at the
two temperatures). The method was optimized for cuvette mea-
surement, but it could be easily adapted to microtiter wells and a
ﬂuorescent plate reader. Fig. 2A reports the emission spectra from
a representative experiment in which binding of AM1 to RBC was
evaluated. The continuous top line (a) is the ﬂuorescence of AM1
at 1 lM. The dashed line (b) represents the ﬂuorescence of AM1
measured in the presence of RBC supernatant; it shows the
quenching of AM1 by free Hb and is used as a reference spectrum
instead of the top line (a). The decreased emission of AM1 in the
presence of RBC, which indicates binding of AM1 to RBC, is de-
picted by the dotted line (c). The bottom line (d) represents the
baseline ﬂuorescence of free Hb in the supernatants from control
RBC.
Therefore, for each experiment, the percentage binding of each
drug to RBC can be calculated using the following equation:
%binding ¼ ðc  dÞ=ðb dÞ  100;
where the letters represent the areas under the curve of the corre-
sponding spectra. In the experiment of Fig. 2A, 20% of AM1 ﬂuores-
cence disappeared from the supernatant of treated RBC. This
corresponds to approximately 400 pmol of AM1 bound/internalized
by RBC at 2% Htc. Because method A gives an indirect estimate of
the amount of drug bound to RBC, method B was developed to pro-vide a precise quantiﬁcation and the cellular distribution of the
drugs.
For method B, the ﬁrst set of tests was conducted to ﬁnd the
best experimental conditions for a quantitative extraction of CQ
from the RBC suspension, minimizing interferences due to the
presence of ferriprotoporphyrin IX (FP), a by-product of Hb degra-
dation. The experiments were conducted by extracting mixtures
made of different amounts of CQ (0.5–25 nmol) and RBC (50–
150 ll of packed RBC corresponding to 0.5–1.5  109 cells). Sam-
ples were subjected to an organic extraction in acidic conditions
by 1 ml of CHCl3/1 N HCl (0.8:1, v/v). The suspension was mixed
vigorously and centrifuged at maximum speed for 10 min. By this
protocol, CQ is solubilized in the protonated form in the aqueous
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in the organic phase. A proper aliquot of the aqueous acid fraction
was diluted to 2 ml with 1 N HCl and corrected to basic pH by
245 ll of 10 N NaOH prior to ﬂuorescence measurements. For each
compound, a calibration curve was calculated by extracting
increasing concentrations of the drug (2–25 nmol) in a free cell
system. Binding of drugs to RBC was quantiﬁed by incubating
500 ll of RBC at 15% Htc in PBS–5 mM glucose buffer at 37 C with
different amounts of the drug (10–50 lM) and for different times
(10–120 min). At the end of incubation, cells were pelleted by cen-
trifugation, washed in PBS–glucose to remove the unbound drug,
and processed as described above. Binding was very rapid, reach-
ing 90% of maximum within 10 min and a plateau after 30 min of
incubation (data not shown).
As reported in Fig. 2B, binding of AM1, AP4b, or CQ was dose
dependent and linearly related to the amount of drug in the
medium. The higher values of binding of AP4b and AM1 can
be ascribed to the higher lipophilicity (compared with CQ) of
the bicyclic substituent, improving cellular permeation. A linear
relation between the number of RBC and the amount of drug
recovered in the acid aqueous phase was observed, with a num-
ber of cells equal to or minor of 109 (25–30 mg Hb) (see inset),
whereas higher values of Htc did not allow a complete recovery
of the drug (data not shown). For this reason, further experi-
ments were performed by incubating 500 ll of RBC at 15% Htc
(750  106 RBC).
To distinguish between CQ internalized and CQ bound to the
membrane, in some experiments at the end of incubation RBC
were pelleted, washed in PBS–glucose, and lysed by hypotonic
shock as reported previously [8]. Membranes were isolated and
washed until free of Hb and were extracted as described for
whole RBC. The amount of CQ entrapped in the membrane
was approximately 10% of the total (0.1 pmol/106 RBC vs.
0.98 pmol/106 RBC). As expected, and in agreement with Bray
and coworkers [7], when CQ and RBC were coincubated in the
presence of FP (10 lM), the drug bound to RBC was more than
twice that measured in the absence of FP (2.32 pmol/106 RBC)
and CQ entrapped in the membrane increased from 10% to
approximately 50% (1.3 pmol/106 RBC).
Whenmethods A and B were compared and the drug concentra-
tion was adjusted for the number of RBC, no signiﬁcant differences
were found between the number of picomoles of CQ bound to 106
RBC calculated by method A and that recovered in RBC after extrac-
tion by method B (0.33 ± 0.14 and 0.25 ± 0.04, respectively, n = 5).
Analytical precision and accuracy were evaluated for method B
by interassay (10 samples during a 1-week period) and intraassay
precision data (n = 10) spiked with 10, 25, or 50 lM CQ, and coef-
ﬁcients of variation were less than 10%.Preliminary experiments demonstrated that the two methods
can be easily applied to Pf-infected RBC. As expected, infected
RBC seem to bind more CQ compared with normal RBC. Further
investigations are in progress to extend this ﬁnding to other quin-
oline-type compounds.
In summary, we have developed two simple and inexpensive
ﬂuorimetric methods to quantify the amount of CQ or related quin-
olines bound or being internalized by human RBC. The procedure,
based on the high ﬂuorescence of the quinoline ring, is rapid, is
reproducible, and can afford good precision and accuracy; there-
fore, it is suitable when comparing new quinolines not available
in the radioactive form.
Method A is faster, but it gives an indirect estimate of drug
binding to RBC and it could be suggested as initial screening of
new compounds. Method B is more time-consuming, but it allows
an accurate quantiﬁcation of the amount of drug bound to RBC
membranes or internalized by RBC.
Both methods could provide useful information during the pre-
clinical assessment of the drug likeness of new molecules.
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